PubMed Health⌕ Search

Biomedical subjects

Stephen Cole

Publications and source records attributed to Stephen Cole.

3 recordsLinked to original sources

Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice.

OBJECTIVE: To document the prevalence of anemia among patients admitted to intensive care (ICU) and, among survivors, at ICU discharge when restrictive transfusion practice was used. DESIGN: This was an observational cohort study. SETTING: Ten of the 26 general ICUs in Scotland. PATIENTS AND PARTICIPANTS: One thousand twenty-three sequential ICU admissions over 100 days, representing 44% of all ICU admissions in Scotland during the study period, studied daily from admission to discharge or death in the ICU. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: The median transfusion trigger used, in the absence of bleeding, was 78 g/l (interquartile range 73-84); <2% of transfusion triggers were above the upper limit of the national transfusion trigger guideline (100 g/l). Overall, 25% of admissions had a hemoglobin concentration <90 g/l at ICU admission. Seven hundred sixty-six patients admitted survived to ICU discharge. Among these, the prevalence of anemia (male <130 g/l; female <115 g/l) at ICU discharge was 87.0 (95% CI: 83.6 to 89.9)% for males and 79.6 (74.8 to 83.7)% for females. Of the male survivors 24.1 (20.3 to 28.3)% and of the female 27.9 (23.4 to 33.2)% had a hemoglobin <90 g/l at ICU discharge. The prevalence was similar for patients with and without pre-existing ischemic heart disease. Logistic regression found independent associations between having a hemoglobin concentration <90 g/l at ICU discharge and the first measured hemoglobin in ICU, the presence of acute renal failure and thrombocytopenia during ICU stay. CONCLUSIONS: Anemia is highly prevalent in ICUs that use restrictive transfusion triggers. The impact of anemia on functional recovery after intensive care requires investigation.

Anemia↗

Tocolysis: current controversies, future directions.

The use of tocolytic agents for the treatment of preterm labor is not supported by the current evidence from placebo-controlled trials. Despite this, tocolytics continue to be widely used in clinical practice. Possible reasons for the lack of observed benefit include the hypothesis that suppression of labor may be harmful in some situations, along with a failure to appreciate the implications of the complex physiology of parturition. Importantly, however, it must be recognized that the quality of evidence addressing the question is poor, with studies significantly underpowered to detect changes in health outcomes. Where tocolysis is used, recent trends have favored agents with lower maternal side effect profiles, including calcium channel blockers and the oxytocin receptor antagonist atosiban. The use of cyclooxygenase-selective inhibitors of prostaglandin synthesis is currently being explored. Future directions in tocolytic research include the use of multiple agent therapies, along with the development of more selective treatments with low side effect profiles. Such agents include oxytocin receptor antagonists with more favorable pharmacological properties and prostaglandin F2alpha receptor antagonists. Future research into tocolytic therapies must focus on evaluating health outcomes from treatments rather than simply the ability to prolong pregnancy, and consequently the design of appropriate clinical studies needs careful consideration with respect to issues such as inclusion criteria, sample size and the selection of appropriate outcome measures.

Animals↗